The appetite among #USbiotechs for #IPOs shows no signs of being satisfied, with three more companies – #ADARxPharma, #TRexBio, and #RetensionPharma – joining the lunch queue.
pharmaphorum.com/news/adarx-t...
pharmaphorum.com/news/adarx-t...
September 22, 2026 at 8:18 AM
The appetite among #USbiotechs for #IPOs shows no signs of being satisfied, with three more companies – #ADARxPharma, #TRexBio, and #RetensionPharma – joining the lunch queue.
pharmaphorum.com/news/adarx-t...
pharmaphorum.com/news/adarx-t...
🧬 IPO Watch: #$ADRX (@ADARxPharma) debuts on Nasdaq Sep 25! Late-clinical siRNA biotech targeting hepatic diseases. Pricing $15-$17, raising $350M at a ~$1.64B cap. Net loss -$87.87M — classic pre-revenue biotech burn. Big-name pipeline, big-name risk. 💊 [NOT FINANCIAL ADVICE, DYOR!] 🙏 —Humble Trader
September 22, 2026 at 10:24 PM
🧬 IPO Watch: #$ADRX (@ADARxPharma) debuts on Nasdaq Sep 25! Late-clinical siRNA biotech targeting hepatic diseases. Pricing $15-$17, raising $350M at a ~$1.64B cap. Net loss -$87.87M — classic pre-revenue biotech burn. Big-name pipeline, big-name risk. 💊 [NOT FINANCIAL ADVICE, DYOR!] 🙏 —Humble Trader